NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve use of chimeric antigen receptor (CAR) T cell therapy for large B cell lymphoma (LBCL) and management of care for cancer survivors. After hearing and assimilating this program, the clinician will be better able to:
1. Compare the efficacy and safety of currently available and emerging autologous and allogeneic CAR T cell therapies for management of lymphomas.
2. Evaluate the efficacy of CAR T cell therapy as second-line treatment in patients with relapsed-refractory LBCL.
3. Develop an updated algorithm that incorporates CAR T cell therapy in the management of refractory LBCL.
4. Identify components of high-quality cancer survivorship care.
5. Use various resources and practical steps to improve the quality of cancer survivorship care in clinical practice.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2022-09-22 05:00:00
- End Date: 2022-09-22 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all